TG Therapeutics, Inc.
BRIUMVI
relapsing forms of multiple sclerosis (RMS)
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for BRIUMVI (relapsing forms of multiple sclerosis (RMS)) is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 14h ago
“NEW YORK, May 27, 2026 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BR”